Has Joseph Bozzo, PA received payments from drug or device companies?

Yes. Drug and device makers reported $1,207 in general payments to Joseph Bozzo, PA across 57 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Joseph Bozzo, PA did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Joseph Bozzo, PA come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Joseph Bozzo, PA

Medical · West Reading, PANPI 1295966935

Payments from drug & device makers

$1,207in general payments, 2019–2025

Across 57 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Gilead$433
Viiv Healthcare Company$359
Paratek Pharmaceuticals, Inc.$145
Shionogi Inc$125
Theratechnologies Inc.$56
AbbVie$43
plus $46 from 2 others

What the payments were for

Food & beverage$1,207100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Gilead	26	$433
Viiv Healthcare Company	22	$359
Paratek Pharmaceuticals, Inc.	2	$145
Shionogi Inc	1	$125
Theratechnologies Inc.	2	$56
AbbVie	2	$43
Merck	1	$24
Melinta Therapeutics, LLC	1	$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Fetroja$125
NUZYRA$125

How this compares

$1,207 in reported general payments places this provider in the 70th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$28,325

Medicare patients

220

Services billed

385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala	331	$1,235,700
TivicayDolutegravir Sodium	74	$187,693
JulucaDolutegravir/Rilpivirine	42	$134,968
CabenuvaCabotegravir/Rilpivirine	18	$113,182
GenvoyaElviteg/Cob/Emtri/Tenof Alafen	23	$89,727
TriumeqAbacavir/Dolutegravir/Lamivudi	19	$73,780
DescovyEmtricitabine/Tenofov Alafenam	34	$70,835
OdefseyEmtricitab/Rilpiviri/Tenof Ala	18	$59,188
PifeltroDoravirine	23	$39,362
DovatoDolutegravir Sodium/Lamivudine	13	$34,052
Cefadroxil	70	$4,262
Cefpodoxime Proxetil	27	$3,934
Vancomycin Hcl	17	$2,861
Doxycycline Monohydrate	26	$2,219
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	20	$1,534

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GileadBiktarvy, Genvoya, Descovy	$433	$1,396,262388 claims
Viiv Healthcare CompanyTivicay, Juluca, Cabenuva, Triumeq, Dovato	$359	$543,676166 claims
MerckPifeltro	$24	$39,36223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,594 medical providers in Pennsylvania.